Kevin S. Gorski, Ph.D.
Affiliations: | 2001 | Johns Hopkins University, Baltimore, MD |
Area:
Molecular Biology, Immunology, Cell BiologyGoogle:
"Kevin Gorski"Parents
Sign in to add mentor| Drew M. Pardoll | grad student | 2001 | Johns Hopkins | |
| (Isolation of genes selectively expressed in mouse bone marrow derived dendritic cells.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Dummer R, Gyorki DE, Hyngstrom J, et al. (2019) Primary 2-year (yr) results of a phase II, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma Annals of Oncology. 30 |
| Ribas A, Dummer R, Puzanov I, et al. (2018) Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 174: 1031-1032 |
| Tchao N, Gorski K, Yuraszeck T, et al. (2018) PS7:135 Amg 592 is an investigational il-2 mutein that induces highly selective expansion of regulatory t cells Lupus Science & Medicine. 5 |
| Gorski KS, Stern J, Hsu Y-, et al. (2018) THU0031 Phenotype of foxp3+ regulatory t-cells expanded by the il-2 mutein, amg 592 in healthy subjects in phase 1, first-in-human study Annals of the Rheumatic Diseases. 77: 243-243 |
| Gogas H, Samoylenko I, Schadendorf D, et al. (2018) Talimogene laherparepvec (T-VEC) treatment increases intratumoral effector T-cell and natural killer (NK) cell density in noninjected tumors in patients (pts) with stage IIIB–IVM1c melanoma: Evidence for systemic effects in a phase II, single-arm study Annals of Oncology. 29: viii443 |
| Ribas A, Dummer R, Puzanov I, et al. (2017) Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 170: 1109-1119.e10 |
| Tchao N, Gorski KS, Yuraszeck T, et al. (2017) Amg 592 Is an Investigational IL-2 Mutein That Induces Highly Selective Expansion of Regulatory T Cells Blood. 130: 696-696 |
| Puzanov I, Milhem MM, Minor D, et al. (2016) Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology |
| Long GV, Dummer R, Ribas A, et al. (2016) Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma. Journal of Clinical Oncology. 34: 9568-9568 |
| Althammer S, Steele K, Rebelatto M, et al. (2016) 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts Journal For Immunotherapy of Cancer. 4 |